Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above 50-Day Moving Average - Should You Sell?

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report)'s share price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $1.67 and traded as high as $3.00. Spero Therapeutics shares last traded at $2.90, with a volume of 1,154,749 shares traded.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Spero Therapeutics to a "hold" rating in a research note on Saturday, June 21st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Spero Therapeutics presently has an average rating of "Hold" and a consensus target price of $5.00.

Spero Therapeutics Stock Performance

The firm has a 50 day simple moving average of $1.67 and a two-hundred day simple moving average of $1.13. The company has a market capitalization of $162.14 million, a PE ratio of -2.27 and a beta of 1.28.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.30. Spero Therapeutics had a negative return on equity of 123.50% and a negative net margin of 156.48%. The firm had revenue of $5.87 million during the quarter, compared to the consensus estimate of $11.00 million. Research analysts expect that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current fiscal year.

Institutional Trading of Spero Therapeutics

Hedge funds have recently made changes to their positions in the company. Anson Funds Management LP increased its stake in shares of Spero Therapeutics by 98.9% during the first quarter. Anson Funds Management LP now owns 7,638,818 shares of the company's stock worth $5,500,000 after acquiring an additional 3,798,932 shares during the period. Monimus Capital Management LP purchased a new stake in Spero Therapeutics in the 4th quarter valued at approximately $320,000. Mackenzie Financial Corp increased its position in Spero Therapeutics by 487.9% during the 4th quarter. Mackenzie Financial Corp now owns 187,559 shares of the company's stock worth $193,000 after purchasing an additional 155,656 shares during the period. Renaissance Technologies LLC increased its position in Spero Therapeutics by 13.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,105,591 shares of the company's stock worth $1,139,000 after purchasing an additional 130,938 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Spero Therapeutics by 26,011.9% during the 4th quarter. JPMorgan Chase & Co. now owns 61,624 shares of the company's stock worth $63,000 after buying an additional 61,388 shares in the last quarter. Institutional investors and hedge funds own 25.60% of the company's stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.